Onconetix (ONCO) 10-K Summary — Year Ended Dec 31, 2025

Onconetix, Inc. is a biopharmaceutical company that has shifted focus from a halted commercial launch to the commercialization of Proclarix and future product candidates. The company reported a significant decline in revenue and continued operating losses, with cash used in operations exceeding available resources, raising substantial doubt about its ability to continue as a going concern.

The company's operations have been primarily devoted to seeking licenses, research and development, potential asset and business acquisitions, and expenditures related to the now halted commercial launch of ENTADFI and the commercialization of Proclarix. The company expects to continue incurring significant operating losses for the foreseeable future as it pursues its strategic growth initiatives.

Revenue fell sharply from the prior year, while operating income and net income remained deeply negative. Operating cash flow was also negative, reflecting continued cash consumption from operations.

The company has incurred substantial operating losses since inception and expects to continue doing so, with no sustained positive cash flows established. As of the latest balance sheet date, the company had a working capital deficit and an accumulated deficit, and cash on hand was insufficient to cover near-term operating needs, raising substantial doubt about its ability to continue as a going concern.

The company raised capital through Series D and Series E Preferred Stock financings during the year, which provided additional cash flow to support near-term operations. However, the company continues to generate recurring net operating losses and has not yet achieved sustained positive cash flows to support its strategic growth initiatives.

Monitor whether the company can secure additional financing or achieve a material improvement in cash flow from operations to address the substantial doubt about its ability to continue as a going concern.